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ABSTRACT 34 
Background 35 
Allergic diseases are common and represent a considerable health and economic burden worldwide. 36 
We aimed to examine the effect of a combination of two probiotic strains administered in late 37 
infancy and early childhood on the development of allergic diseases and sensitization. 38 
Methods 39 
In this double-blind, placebo-controlled intervention trial, participants were randomized to receive a 40 
daily mixture of Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis or placebo – 41 
starting prior to attending daycare. The intervention period was 6 months, and the parents answered 42 
web-based questionnaires on allergic symptoms and doctor’s diagnosed allergic disease monthly. 43 
IgE was measured at baseline and follow-up.  44 
Results 45 
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A total of 290 participants were randomized; 144 in the probiotic group and 146 in the placebo 46 
group. Mean age at intervention start was 10.1 months. At follow-up (mean age 16.1 months), the 47 
incidence of eczema was 4.2% in the probiotic group and 11.5% in the placebo group (p = 0.036). 48 
The incidence of asthma and conjunctivitis did not differ between groups, and no children presented 49 
with rhinitis. Sensitization was equal in the two groups at intervention start (7.5% and 9.5% 50 
respectively), and two children in each group were sensitized during the intervention.  51 
Conclusions 52 
We observed a significantly lower incidence of eczema in the probiotic group compared to the 53 
placebo group. The probiotics were administered in late infancy – prior to attending day care – 54 
suggesting a broader window of opportunity using probiotics in the prevention of eczema. The 55 
incidence of asthma, rhinitis, conjunctivitis and sensitization did not differ. 56 
 57 
Clinical Trial Registration 58 
Effect of Probiotics in Reducing Infections and Allergies in Young Children Starting Daycare 59 
(ProbiComp), NCT02180581. https://clinicaltrials.gov/ct2/show/NCT02180581 60 
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INTRODUCTION 65 
Allergic diseases in childhood consist of eczema, asthma, rhino-conjunctivitis and food allergies. In 66 
2014 it was estimated, that 11.6% of children under the age of 18 years suffer from eczema, 8.4% 67 
from rhinitis, 10% from respiratory allergies, and 5.4% from food allergies in the United States (1). 68 
In a 2015 estimate, one third of children in Denmark and Sweden was affected by at least one 69 
allergic disease at 5 years of age (2). Allergic diseases present a considerable health and economic 70 
burden; and might diminish the quality of life (3, 4), making the prevention of the development of 71 
these diseases an important task. 72 
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In the last decades, the interest in the preventive effects of probiotics (defined by the World Health 73 
Organization (WHO) as “live microorganisms which when administered in adequate amounts 74 
confer a health benefit on the host” (5)) has increased. 75 
In 2012, Pelucchi et al. published a meta-analysis on the use of probiotics in prevention of atopic 76 
dermatitis (6). They concluded that probiotics play a moderate role in preventing atopic dermatitis if 77 
administered in pregnancy/early life to mother, child or both. A similar conclusion was drawn by 78 
Cuallo-Garcia et al. in a systematic review and meta-analysis from 2015, whereas no preventive 79 
effect on other allergic diseases was observed (7). 80 
Due to the beneficial effects on the development of eczema, The World Allergy Organization 81 
guideline panel suggested in 2015 to use probiotics in pregnant women at high risk of having an 82 
allergic child; women, who breastfeed infants at high risk of developing allergy; and infants at high 83 
risk of developing allergy (8). In a systematic review from 2014 on food allergy, The European 84 
Academy of Allergy and Clinical Immunology (EAACI) did not find evidence to support the use of 85 
probiotics in the prevention of food allergy (9). 86 
Overall, studies on probiotics have shown conflicting results, and the heterogeneity of studies on 87 
probiotics and the development of allergic diseases is a pitfall in the interpretation of the results 88 
(10).  89 
Most studies investigating the prevention of the development of allergic diseases by probiotics 90 
administer probiotics either to the mother during pregnancy, to the infant during early infancy, or 91 
both, whereas administration in late infancy has not previously been examined. 92 
As part of the ProbiComp Study (11), we aimed to investigate the effect of Lactobacillus 93 
rhamnosus (LGG) in combination with Bifidobacterium animalis subsp. lactis (BB-12) 94 
administered in late infancy – prior to attending daycare – on the development of allergic diseases 95 
and sensitization in terms of doctor’s diagnosed allergic disease, elevated specific IgE levels, and 96 
parentally observed and reported food reactions. 97 
 98 
METHODS 99 
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In the following, “allergic disease” covers doctor’s diagnosed asthma, allergic rhinitis, allergic 100 
conjunctivitis, and eczema; whereas “food reaction” covers parentally observed recurrent reactions 101 
to food sources. 102 
Participants 103 
The ProbiComp Study is a randomized, double-blind, placebo-controlled intervention trial designed 104 
to investigate the effect of probiotics on absence from daycare due to respiratory or gastrointestinal 105 
infections in infants aged 8-14 months (11). Inclusion period was August to December 2014 and 106 
August to December 2015.  Infants expected to start daycare within 12 weeks after intervention start 107 
were assigned by block randomization to receive either daily probiotics or placebo for a 6 months’ 108 
period. Inclusion criteria were birthweight > 2500 g, gestational age > 36 weeks, being single-born, 109 
and expected to start in daycare at age 8-14 months between September and February. Exclusion 110 
criteria were severe chronic illness, regular medication (including proton pump inhibitors), 111 
antibiotic treatment within 4 weeks prior to baseline examination, and non-Danish speaking parents. 112 
Written, informed consent was given by parents or legal guardians of 290 participants. Baseline 113 
examination including a structured interview, anthropometric measurements, and a venous blood 114 
sample was conducted after randomization, but prior to intervention start. The procedure was 115 
repeated at the end of the intervention, 6 months later. Anthropometric measurements were weight 116 
and length, but none of these are included in the present manuscript. 117 
 118 
Intervention 119 
Intervention started the day following the baseline examination. The intervention group received 120 
sachets of 1.0 g maltodextrin supplemented with LGG and BB-12 each in a dose of 109 colony 121 
forming units (CFU), and the placebo group received maltodextrin only. LGG/BB-12 and placebo 122 
sachets were identical in appearance, smell and taste. Both LGG and BB-12 are registered 123 
trademarks of Chr. Hansen A/S (Hørsholm, Denmark) and were provided by Chr. Hansen A/S free 124 
of charge. To review the isolated effect of LGG/BB-12, fermented dairy products supplemented 125 
with probiotics were prohibited two weeks prior to and within the intervention period. Un-126 
supplemented yogurt was allowed 1-2 times per week. There were no restrictions on the use of 127 
infant formulas, whether or not the formula contained pro- or prebiotics. 128 
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 129 
Endpoint measures 130 
The structured interview at baseline contained questions on family and household characteristics as 131 
well as allergic disease prior to enrolment. During the intervention period of 6 months, parents were 132 
to monthly register symptoms and diagnosis of allergic disease as well as reactions to foods (milk, 133 
egg, fish, peanuts, other nuts (e.g. almonds or hazelnuts), flour products, legumes, fruit, and 134 
vegetables) in a web-based questionnaire. The questions on allergic symptoms were previously 135 
validated in a prospective birth cohort study, where infants were diagnosed with atopic eczema 136 
using five different criteria; Hanifin and Rajka, Schultz-Larsen, Danish Allergy Research Centre 137 
(DARC), doctor’s diagnosed visible eczema, and (as used in the present study) the U.K. Working 138 
Party’s diagnostic criteria using discriminatory features from Hanifin and Rajka in a questionnaire 139 
form (12).  140 
Sensitization was defined using the ImmunoCAP® Phadiatop® Infant blood test (Phadia AB, 141 
Sweden), which is an in vitro qualitative and semi-quantitative assay for graded determination of 142 
specific IgE antibodies to food and inhalant allergens that are relevant in the development of atopy 143 
in younger children. The allergens included in the test are: cow’s milk, hen’s egg, peanut, shrimp, 144 
cat, dog, Dermatophagoides pteronyssinus, birch, timothy, ragweed, and Parietaria judaica (13). 145 
Results are expressed as Phadia Arbitrary Units (PAU)/L indicating the degree of sensitization, and 146 
values  ≥ 0.35 PAU/L were considered positive, i.e. the child was classified as sensitized. 147 
Furthermore, specific IgE levels against a panel of food and inhalant allergens were determined 148 
(ImmunoCAP ISAC™, Thermo-Fischer Scientific, Denmark) in sensitized children. 149 
 150 
Statistics 151 
Descriptive statistics were performed to describe the participants, their family and household 152 
characteristics. Continuous variables are presented as mean (SD) if normally distributed, otherwise 153 
as median (IQR), categorical variables as n (%). 154 
The outcomes of the present analysis within the ProbiComp Study were 1) the incidence of allergic 155 
disesses during the intervention period, 2) the incidence of sensitization, i.e. ImmunoCAP® 156 
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Phadiatop® test with specific IgE ≥ 0.35 PAU/L at the end of the intervention, 3) the incidence of 157 
food reactions during the intervention period. Finally, a composite outcome in terms of “any 158 
allergic disease”, i.e. asthma, rhinitis, conjunctivitis, and eczema was included and analyzed 159 
separately. A per protocol approach was chosen due to non-availability of outcome measurements 160 
among drop-outs.  Furthermore, for every outcome, children already affected at baseline were 161 
excluded at follow-up, e.g. children with eczema at baseline were excluded when assessing the 162 
incidence of eczema during the intervention period. 163 
Outcome incidences were compared by chi2
 166 
 test, p < 0.05 was considered significant. Statistical 164 
analyses were performed using STATA IC/14.2 (Texas, USA). 165 
Ethics 167 
The study was approved by the Committees on Biomedical Research Ethics for the Capital Region 168 
of Denmark (H-4-2014-032), and registered at www.clinicaltrials.org (NCT02180581). 169 
 170 
RESULTS 171 
Participants 172 
A total of 290 children were randomized, 144 to the intervention group and 146 to the placebo 173 
group. A detailed flowchart of the study recruitment is presented elsewhere (11). In summary, five 174 
children dropped out after randomization, but prior to baseline examination (1 from the probiotic 175 
and 4 from the placebo group). The remaining 285 children had a mean age of 10.1 months (SD 176 
0.7) at baseline examination and intervention start. Baseline characteristics were equally distributed 177 
in the two groups (Table 1). Of the 285 children, 25 (8.8%) dropped out during the intervention, 13 178 
from the probiotic and 12 from the placebo group.  Mean age at follow-up was 16.1 months (SD 179 
0.9). 180 
Fecal samples from baseline and follow-up was obtained from 201 children, and their gut 181 
microbiota composition has recently been described in detail elsewhere (14). To summarize, LGG 182 
and BB-12 was detected in 91% and 95%, respectively, of the fecal samples from the probiotic 183 
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group, and in 2% and 31%, respectively, of the fecal samples from the placebo group at follow-up. 184 
Noteworthy, the BB-12 primer was subspecies specific, as opposed to strain specific (14). 185 
 186 
Allergic disease 187 
Regarding allergic disease, no children were diagnosed with asthma, rhinitis, or conjunctivitis at 188 
baseline, whereas a total of 19 children were diagnosed with eczema, 11 in the probiotic and 8 in 189 
the placebo group. The follow-up groups for asthma, rhinitis, and conjunctivitis therefore comprised 190 
260 children (130 in each group), and the follow-up groups for eczema and any allergic disease 191 
comprised 241 children (119 in the probiotics and 122 in the placebo group). 192 
As shown in Table 2, a total of 19 children developed eczema during the intervention; 5 (4.2%) in 193 
the probiotic group and 14 (11.5%) in the placebo group (p = 0.036), corresponding to a relative 194 
risk of 0.37 (95% CI 0.14-0.98). The incidence of the other allergic diseases did not differ across 195 
groups. Regarding the composite endpoint “any allergic disease”, 9 (7.6%) in the probiotic group 196 
and 23 (18.9%) in the placebo group were affected (p = 0.010), in both groups driven by eczema 197 
(55.5% and 60.9% in the probiotics and placebo group, respectively).  198 
 199 
Sensitization 200 
A total of 153 children had both baseline and follow-up IgE measured; 80 in the probiotic and 73 in 201 
the placebo group. Of these, 13 were sensitized at baseline; 6 (7.5%) in the probiotic, and 7 (9.6%) 202 
in the placebo group, and the follow-up group therefore comprised 140 children; 74 in the probiotic 203 
and 66 in the placebo group. During the intervention, two in each group developed sensitization (p 204 
= 0.910). 205 
 206 
Food reactions 207 
A total of 27 children had food reactions at baseline; 13 (9.1%) in the probiotic and 14 (9.9%) in the 208 
placebo group, leaving a total of 233 children in the follow-up group; 117 in the probiotic and 116 209 
in the placebo group. Twenty-five children presented with newfood reactions during the 210 
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intervention according to parental report, 12 (10.2%) in the probiotic and 13 (11.2%) in the placebo 211 
group (p = 0.814). 212 
 213 
DISCUSSION 214 
In this double-blind, placebo-controlled study, participants were randomized to receive either a 215 
mixture of two strains of probiotics (LGG/BB-12) or placebo in late infancy, prior to attending 216 
daycare. Despite the late start of administration (mean age 10.1 months), we observed a 217 
significantly lower incidence of eczema in the probiotic group compared to placebo during the 218 
intervention. Concerning other allergic diseases, we observed no differences in incidences between 219 
the groups, which could be due to a later onset of these diseases. Neither did we observe any 220 
differences in the incidences of sensitization or food reactions. 221 
Whereas most other studies have included participants based on either maternal allergic disease or 222 
first degree relative with allergic disease (15-22), participants in the ProbiComp study were 223 
unselected. However, more than half of the children (in both groups) had a first degree relative with 224 
a history of allergic disease. This is in line with previous, unselected studies (23-24), and probably 225 
reflects a high frequency and awareness of allergic diseases in the population, and a greater intent to 226 
participate within families with allergic diseases. 227 
The high detection rate (> 90%) of LGG/BB-12 in fecal samples of the probiotic group indicates a 228 
high level of compliance. However, BB-12 was also detected in 31% of the placebo group fecal 229 
samples at follow-up. This could be due to the BB-12 primer being subspecies and not strain 230 
specific, suggesting detection of endogenous Bifidobacterium animalis subsp. lactis or due to prior 231 
ingestion of related strains through infant formula (14). From baseline to an age of 12.8 months (SD 232 
1.4), 91 children in the placebo group used infant formulas, and of these, 26 had used formulas 233 
containing probiotics (11). Wider dietary restrictions were considered during planning of the study, 234 
i.e. prohibiting the use of infant formulas containing pre- and/or probiotics, but there was concern, 235 
that it would result in difficulties recruiting participants, since a majority of currently available 236 
infant formulas in Denmark contain pre- and/or probiotics. 237 
Regarding the use of the combination of LGG and BB-12, Huurre et al. in 2008 investigated pre- 238 
and postnatal maternal administration of a combination of LGG and BB-12. Eczema was developed 239 
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in 17.6% of the placebo group and 9.7% of the probiotics group, though not reaching statistical 240 
significance (p = 0.131) (25).   241 
LGG used in combination with other probiotics has also yielded conflicting results. Regarding 242 
maternal administration, Dotterud et al. in 2010 used administration of three strains of probiotics, 243 
LGG, BB-12 and Lactobacillus acidophilus LA5, pre- and postnatally. The cumulative incidence of 244 
eczema at the age of two and 6 years was reduced (23, 26). Supporting this, Rautava et al. in 2012 245 
observed a protective effect of a combination of Bifidobacterium longum and LGG or a 246 
combination of Bifidobacterium longum and Lactobacillus paracasei on the development of 247 
eczema, when administered to the mother in pregnancy and during breastfeeding (20). 248 
Administration of LGG and Bifidobacterium longum (BL999) directly to the child in infant formula 249 
from birth until 6 months of age was examined by Soh et al. in 2009, and no preventive effect on 250 
the development of eczema at two years of age was observed (21).  251 
The use of LGG as a single strain of bacteria in relation to allergic diseases has been investigated 252 
several times. Kalliomäki et al. in 2001 (16) observed a protective effect of LGG on the incidence 253 
of eczema when given prenatally to the mother and after birth to the infant, whilst no effect on the 254 
development of other allergic diseases was observed. Wickens et al. in 2008 had similar findings 255 
for Lactobacillus rhamnosus strain HN001 including a protective effect up to 4 years of age (22, 256 
29). In two long term follow-up studies, Kalliomäki et al. observed that the preventive effect 257 
extended to 4 and 7 years of age, respectively (27-28). Yet, Kopp et al. in 2008 (18) and Ou et al. in 258 
2012 (30) did not reproduce these findings at follow-up at 2 years of age (Kopp et al.) and at 6, 18, 259 
and 36 months of age (Ou et al.).  260 
To our knowledge, only one other study has investigated the effects of probiotics administered in 261 
late infancy on the development of allergic disease. West et al. used Lactobacillus paracasei ssp. 262 
administered during weaning, i.e. from four to 13 months of age, and observed a reduced incidence 263 
of eczema at 13 months of age (24).  264 
Regarding sensitization, our null-findings are in line with findings from previous studies (15-16, 18-265 
21, 24, 30). This is also the case with food reactions, where we observed no differences between the 266 
two groups. Kukkonen et al. observed no differences on the development of food allergies between 267 
probiotics and placebo groups, providing the probiotics for the mother 2-4 weeks prior to delivery 268 
and to the infant for 6 months thereafter (19). Cuello-Garcia et al. did not find evidence in a 269 
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systematic review and meta-analysis to support the effects of probiotics to reduce the risk of allergic 270 
diseases, other than eczema (7). Finally, EAACI does not support the use of probiotics in the 271 
prevention of food allergy in their guidelines (9). 272 
A limitation of the present analysis is that sample size was based on the primary outcome of the 273 
ProbiComp study, i.e. absence from daycare due to infections (11). Despite this, we observed 274 
significant differences in the development of eczema, and regarding allergic diseases other than 275 
eczema, we probably would not have benefited from a larger sample size, since asthma, rhinitis, and 276 
conjunctivitis usually do not develop until later in childhood, and food reactions are likely to have 277 
already occurred prior to the intervention period.  Furthermore, as often observed in randomized 278 
controlled trials including healthy individuals, the ProbiComp study population was self-selected 279 
and consisted of primarily well-educated, high-income families with a special interest in the study 280 
and study participation in general. This may explain the high number of participants completing the 281 
study, which is indeed a strength. 282 
In conclusion, we observed that administration for 6 months of a combination of two strains of 283 
probiotics (LGG and BB-12) starting in late infancy prior to attending daycare, had a preventive 284 
effect on the development of doctor’s diagnosed eczema, but no effects on other allergic diseases, 285 
sensitization or recurrent food reactions. The late timing of the administration of probiotics suggests 286 
an even broader window of opportunity in the prevention of eczema by use of probiotics. 287 
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Table 1 – Baseline characteristics 
All values are n (%) unless otherwise stated. Percentages are based on the group total. 
 Probiotics Placebo 
N 143 142 
Household characteristics 
First degree relative with allergic disease1 83 (58.0) 81 (57.0) 
Older sibling(s) 71 (49.7) 66 (46.5) 
Parental smoking, indoor 1 (0.7) 0 (0.0) 
Parental smoking, outdoor 13 (9.1) 14 (9.9) 
Furry pet2 26 (18.2) 25 (17.6) 
Age at baseline, months 
   mean (SD) 9.98 (0.81) 10.08 (0.88) 
Birth characteristics 
Vaginal birth 111 (77.6) 121 (85.2) 
Female sex 69 (48.3) 71 (50.0) 
Birth weight, grams 
   mean (SD) 3,543 (492) 3,532 (456) 
Nutrition characteristics 
Currently breastfed 72 (50.3) 63 (44.3) 
Duration of exclusive breastfeeding, months 
   median (IQR) 4.0 (1.0-5.0) 4.0 (1.0-4.9)3 
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Use of infant formula at baseline 
   with probiotics 
   with prebiotics 
92 (64.3) 
36 (25.2) 
50 (35.0) 
102 (71.8) 
36 (25.4) 
60 (42.3) 
No use of infant formula at baseline 6 (4.2) 6 (4.2) 
1) Asthma, rhinitis, conjunctivitis, or eczema 
2) E.g. cat, dog, guinea pig, rabbit 
3) n = 140 
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Table 2 – Doctor’s diagnosed allergic disease at follow-up 
All values are n (%) unless otherwise stated. Percentages are based on the group total. A per 
protocol approach was chosen, i.e. N are study population at baseline and follow-up n are study 
population for the specific endpoint after exclusion of censored cases (those who withdrew prior to 
follow-up and those who were already diagnosed at baseline). P values are for chi2 test. 
 Probiotics Placebo p 
N 143 142 
- 
Drop-out prior to follow-up 13 12 
Asthma  
Follow-up n 130 130 
0.309 
Diagnosed at follow-up 3 (2.3) 6 (4.6) 
Rhinitis  
Follow-up n 130 130 
- 
Diagnosed at follow-up 0 (0) 0 (0) 
Conjunctivitis  
Follow-up n 130 130 
0.314 
Diagnosed at follow-up 1 (0.8) 3 (2.3) 
Eczema 
Follow-up n 119 122 
0.036 
Diagnosed at follow-up 5 (4.2) 14 (11.5) 
Any allergic disease  
Follow-up n 119 122 
0.010 
Diagnosed at follow-up 9 (7.6) 23 (18.9) 
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